ProShare Advisors LLC Sells 8,072 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

ProShare Advisors LLC decreased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 19.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 32,877 shares of the company’s stock after selling 8,072 shares during the period. ProShare Advisors LLC’s holdings in Recursion Pharmaceuticals were worth $247,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Wedmont Private Capital boosted its position in shares of Recursion Pharmaceuticals by 11.8% during the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after purchasing an additional 2,000 shares in the last quarter. Interchange Capital Partners LLC lifted its stake in shares of Recursion Pharmaceuticals by 7.3% during the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after buying an additional 2,349 shares in the last quarter. Amalgamated Bank boosted its stake in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the period. Benjamin F. Edwards & Company Inc. purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth approximately $26,000. Finally, Victory Capital Management Inc. grew its position in Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after buying an additional 2,598 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on RXRX. Needham & Company LLC lowered their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. KeyCorp dropped their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Finally, Jefferies Financial Group reduced their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Trading Up 0.8 %

Recursion Pharmaceuticals stock opened at $6.11 on Friday. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $15.74. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -3.82 and a beta of 0.80. The business’s fifty day simple moving average is $6.88 and its two-hundred day simple moving average is $8.09. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business’s revenue for the quarter was up 30.9% compared to the same quarter last year. During the same period last year, the company posted ($0.38) earnings per share. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total value of $83,792.04. Following the transaction, the director now directly owns 7,167,110 shares of the company’s stock, valued at approximately $52,463,245.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $8.13, for a total value of $48,780.00. Following the completion of the sale, the chief operating officer now directly owns 535,457 shares in the company, valued at $4,353,265.41. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total transaction of $83,792.04. Following the transaction, the director now owns 7,167,110 shares in the company, valued at approximately $52,463,245.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 263,129 shares of company stock valued at $1,826,444 over the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.